RCS - Hutchmed China Ltd - Data to be Presented at AACR Annual Meeting 2026

HUTCHMED (China)Announcement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260409:nRSI6582Za&default-theme=true

RNS Number : 6582Z  Hutchmed (China) Limited  09 April 2026

Press Release

 

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

Hong Kong, Shanghai & Florham Park, NJ - Thursday, April 9, 2026:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from
several studies of compounds discovered by HUTCHMED will be presented at the
upcoming American Association of Cancer Research (AACR) Annual Meeting 2026,
taking place on April 17-22, 2026 in San Diego, California.

 

Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR
Antibody-Targeted Therapy Conjugate ("ATTC") will be presented. The payload
of HMPL-A580 potently inhibited PI3K and PIKK family kinases, with IC(50)
ranging around 1 to 10 nM. Eurofins profiling across 418 kinases revealed the
payload has excellent selectivity. By conjugating this potent payload with an
anti-EGFR antibody via a cleavable linker, the ATTC compound HMPL-A580
demonstrated robust anti-tumor effect. Upon binding to EGFR-expression cancer
cell line, HMPL-A580 underwent rapid internalization, lysosomal trafficking,
payload release, and PAM and PIKK signaling inhibition to induce tumor cell
apoptosis. In a 38-human solid tumor cell line panel, HMPL-A580 potently
inhibited EGFR-expression tumor cell proliferation. The tumor cells harboring
EGFR high expression, EGFR mut or PAM alterations were more sensitive to
HMPL-A580. HMPL-A580 showed a strong bystander effect when EGFR-negative cells
co-cultured with EGFR-expression cells. In human tumor xenograft models in
mice, HMPL-A580, administered intravenously at 1~10 mg/kg once weekly for two
weeks, demonstrated a dose / exposure-dependent anti-tumor activity in
multiple EGFR-expression models, which is associated with much stronger target
inhibition and suppression of downstream functions than antibody and payload
alone treatment. The preliminary results demonstrated that HMPL-A580 was
stable in human, monkey, rat and mouse plasma, and showed favorable PK
property in cynomolgus monkeys.

 

Updated results from a multicenter, single-arm Phase Ib/II trial of
surufatinib plus sintilimab and capecitabine in previously treated metastatic
small bowel adenocarcinoma and appendiceal carcinoma, as well as results from
a exploratory Phase II study of surufatinib combined with gemcitabine and
nab-paclitaxel ("AG") for the treatment of locally advanced or metastatic
pancreatic ductal adenocarcinoma patients following AG induction therapy will
also be presented.

 

Details of the presentations are as follows:

 

 Abstract title                                                                  Presenter / Lead author                                             Presentation details
 SPONSORED STUDIES
 Discovery of HMPL-A580, a first-in-class antibody-targeted therapy conjugate    Yu Cai, HUTCHMED, Shanghai, China                                   4549 (https://www.abstractsonline.com/pp8/#!/21436/presentation/4385)
 (ATTC) of a novel PI3K/PIKK inhibitor payload linked to an anti-EGFR antibody

                                                                                                                                                     Poster Session (PO.ET01.03)

                                                                                                                                                     Tuesday, April 21, 2026

 INVESTIGATOR-INITIATED STUDIES
 Updated multicenter phase Ib/II analysis of surufatinib plus sintilimab and     Xiaoyu Xie, The Sixth Affiliated Hospital, Sun Yat-sen University,  CT160 (https://www.abstractsonline.com/pp8/#!/21436/presentation/12160)
 capecitabine in previously treated metastatic small bowel adenocarcinoma and    Guangzhou, China

 appendiceal carcinoma                                                                                                                               Poster Session (PO.CT01.05)

                                                                                                                                                     Monday, April 20, 2026
 Sequential treatment with surufatinib combined with gemcitabine and             Jin Xu, Fudan University Shanghai Cancer Center, Shanghai, China    CT146 (https://www.abstractsonline.com/pp8/#!/21436/presentation/12146)
 nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or

 metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG                                                                             Poster Session (PO.CT01.05)
 induction therapy: A two-cohort, exploratory phase II study

                                                                                                                                                     Monday, April 20, 2026

 

About the ATTC Platform and HMPL-A580

HUTCHMED's ATTC platform represents a next-generation approach to precision
oncology, combining monoclonal antibodies with proprietary small-molecule
inhibitor payloads to deliver dual mechanisms of action. Unlike traditional
cytotoxin-based Antibody Drug Conjugates, ATTCs combine targeted therapies to
achieve synergistic anti-tumor activity and durable responses in preclinical
models, outperforming standalone antibody or small-molecule inhibitor
components in efficacy and safety.

 

The first family of ATTCs are based on a novel payload that targets the
PI3K/AKT/mTOR ("PAM") pathway, a critical intracellular network involved in
cell growth, survival, and division. Alterations in the PAM pathway are
frequently associated with poor prognosis and resistance to treatment across
various cancers. However, existing PAM-targeted drugs face significant
challenges, including on-target toxicities that restrict dosing, feedback
loops that enable pathway reactivation, and insufficient tumor-specific
delivery. Preclinical data from the first ATTC candidate based on this potent
novel PI3K/PIKK inhibitor payload, HMPL-A251, was presented at AACR-NCI-EORTC
in October 2025.

 

HMPL-A580 is the second ATTC candidate based on this novel payload. It is a
first-in-class ATTC comprising a highly selective and potent PI3K/PIKK
small-molecule inhibitor payload linked to an anti-EGFR antibody via a
cleavable linker. EGFR is highly expressed in multiple types of solid tumors
and is well recognized as a driving force in tumorigenesis and disease
progression. By conjugating this highly novel PI3K/PIKK payload to an
anti-EGFR antibody, HMPL-A580 is designed to deliver targeted pathway
inhibition directly into EGFR-expressing tumor cells, thereby potentially
overcoming the systemic toxicity and narrow therapeutic index historically
associated with PI3K/PIKK inhibitors. This approach aims to achieve deeper and
more durable target inhibition while improving the overall tolerability
profile.

 

HUTCHMED has demonstrated how its partnerships leverage the expertise of
multinational pharmaceutical companies to accelerate bringing novel medicines
to address large unmet needs around the world, and plans to apply this
strategy to its ATTC technology this year.

 

About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively
inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast
growth factor receptor (FGFR), which both inhibit angiogenesis, and colony
stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated
macrophages, promoting the body's immune response against tumor cells.
Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA(®).
HUTCHMED currently retains all rights to surufatinib worldwide.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including its expectations regarding the
therapeutic potential of surufatinib, HMPL‑A580 and other drug candidates
from the ATTC platform and the further development of surufatinib, HMPL‑A580
and other drug candidates from the ATTC platform in this and other
indications. Forward-looking statements involve risks and uncertainties. Such
risks and uncertainties include, among other things, assumptions regarding the
timing and outcome of clinical studies and the sufficiency of clinical data to
support an new drug application submission of surufatinib, HMPL‑A580 and
other drug candidates from the ATTC platform in China or other jurisdictions,
its potential to gain approvals from regulatory authorities on an expedited
basis or at all, the efficacy and safety profile of surufatinib, HMPL‑A580
and other drug candidates from the ATTC platform, HUTCHMED's ability to fund,
implement and complete its further clinical development and commercialization
plans for surufatinib, HMPL‑A580 and other drug candidates from the ATTC
platform and the timing of these events. In addition, as certain studies rely
on the use of sintilimab, capecitabine, gemcitabine and nab-paclitaxel, as
combination therapeutics, such risks and uncertainties include assumptions
regarding their safety, efficacy, supply and continued regulatory
approval. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see HUTCHMED's
filings with the US Securities and Exchange Commission, The Stock Exchange of
Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or
revise the information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.

 

CONTACTS
 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
    Ben Atwell / Tim Stamper                            +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGCGDSBXGDGLI



            Copyright 2019 Regulatory News Service, all rights reserved